ACVRL1 and cancer: Despite that ALK1 inhibitors exhibited promising results in a range of different mouse models of cancer [8–11], clinical trials with the receptor decoy dalantercept (Acceleron Pharma) failed to show substantial benefit in different cancer types [12, 13].